deltatrials
Completed PHASE2 NCT00002553

Chemotherapy Plus Radiation Therapy and Biological Therapy in Treating Patients With Hematologic Cancer

TREATMENT OF PATIENTS WITH HEMATOLOGIC MALIGNANCIES USING MARROW TRANSPLANTATION FROM UNRELATED DONORS MATCHED FOR HLA OR INCOMPATIBLE FOR ONE HLA LOCUS ANTIGEN

Sponsor: Fred Hutchinson Cancer Center

Conditions Leukemia Lymphoma
Interventions allogeneic bone marrow transplantation cyclophosphamide low-LET cobalt-60 gamma ray therapy
Updated 6 times since 2017 Last updated: Nov 28, 2011 Started: Aug 31, 1990 Completion: Jun 30, 2003

This PHASE2 trial investigates Leukemia and Lymphoma and is currently completed. Fred Hutchinson Cancer Center leads this study, which shows 6 recorded versions since 1990 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. May 2022 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jan 2021 — May 2022 [monthly]

    Completed PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Aug 1990

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Fred Hutchinson Cancer Center
  • National Cancer Institute (NCI)
Data source: Fred Hutchinson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Seattle, United States